Blog - Gaurav Dakshini

Introduction Cloud SaaS validation in pharma is becoming increasingly important as pharmaceutical companies adopt cloud-based platforms for quality management, laboratory operations, manufacturing, training, document control, regulatory workflows, and business processes. Software as a Service (SaaS) can offer scalability, faster deployment, centralized administration, and access to regularly updated applications. However, using a cloud platform in a regulated pharmaceutical environment introduces important questions about data integrity, system security, supplier oversight, electronic records, change management, and continued fitness for intended use. GAMP 5 provides a risk-based framework for managing GxP computerized systems throughout their lifecycle. Its approach supports the use of supplier expertise, documented risk assessment, and verification activities proportionate to patient safety, product quality, and data integrity risks. ISPE's GAMP 5 guidance also addresses modern technologies, including cloud computing. The key principle is that moving software to the cloud does not remove the pharmaceutical company's responsibility for its regulated processes. Organizations must establish appropriate controls and demonstrate that the configured system remains suitable for its intended use. Introduction1. What Is Cloud SaaS Validation in Pharma?2. Why GAMP 5 Matters for Cloud-Based Systems3. Eight Essential Cloud SaaS Validation ControlsControl 1: Define the intended use and system boundaryControl 2: Perform a documented GxP risk assessmentControl 3: Assess and oversee the SaaS supplierControl 4: Establish user requirements and configuration controlsControl 5: Build risk-based verification and testingControl 6: Protect data integrity and electronic recordsControl 7: Manage cloud updates, incidents, and disaster recoveryControl 8: Maintain lifecycle oversight and periodic review4. A Practical Cloud SaaS Validation Lifecycle5. Common Cloud SaaS Validation Mistakes to AvoidAssuming supplier validation is sufficientTreating every function as equally criticalIgnoring ongoing releasesOverlooking interfaces and data migrationTreating Part 11 as a product certificate6. Frequently Asked QuestionsDoes a SaaS application require validation in pharma?Can supplier documentation be used as validation evidence?What is the role of GAMP 5 in cloud validation?Does every SaaS application need 21 CFR Part 11 controls?How often should a cloud SaaS system be reviewed?Conclusion 1. What Is Cloud SaaS Validation in Pharma? Cloud SaaS validation in pharma is the documented, risk-based process of establishing that a cloud-hosted software application is fit for its intended use in a regulated pharmaceutical activity. In a SaaS model, a supplier generally operates and maintains the underlying application and much of the supporting infrastructure. The customer accesses the application through a network rather than managing all software and hardware locally. This model changes how validation work is planned, but it does not eliminate the need for appropriate assurance. For example, a cloud-based Quality Management System (QMS) may manage deviations, CAPA records, change controls, and training activities. If these records support regulated decisions, the company needs evidence that the configured system and its associated procedures are appropriate for those activities. Not every cloud application is automatically a GxP system. Applicability depends on its intended use, the regulated processes it supports, the records it creates or maintains, and the relevant regulatory requirements. 2. Why GAMP 5 Matters for Cloud-Based Systems GAMP 5 encourages a lifecycle-based, risk-proportionate approach rather than treating every application as if it required identical testing and documentation. For cloud SaaS systems, this means understanding which controls are provided by the supplier, which are configured or managed by the customer, and which require shared oversight. A supplier may provide standard product documentation, release information, security controls, testing evidence, and service-management procedures. These materials can support the customer's assurance activities when their relevance and adequacy are evaluated. The regulated company must still assess whether the evidence covers its intended use, configured workflows, interfaces, electronic records, and business risks. GAMP 5 is industry good-practice guidance, not a substitute for applicable laws or regulations. The validation strategy should reflect the system's actual use and the regulatory framework governing the organization. 3. Eight Essential Cloud SaaS Validation Controls Control 1: Define the intended use and system boundary Start by documenting what the system will do and how it will be used. Identify the GxP processes supported, business owners, affected departments, relevant records, interfaces, user groups, and expected outputs. Define the system boundary, including relevant integrations and dependencies. A clear intended-use statement prevents unnecessary testing of irrelevant functions while helping ensure that critical functions are not overlooked. For example, a training management platform used to maintain regulated training records may require a different assurance approach from a general-purpose collaboration application. Control 2: Perform a documented GxP risk assessment Evaluate how system failure, incorrect configuration, unauthorized access, missing records, or inaccurate data could affect product quality, patient safety, and data integrity. Consider the criticality of electronic records, the significance of automated decisions, the availability of alternative controls, and the potential consequences of incorrect outputs. Use the assessment to establish verification priorities, acceptance criteria, review requirements, and appropriate controls. A risk-based approach does not mean skipping validation activities merely because the supplier hosts the application. It means selecting evidence and testing that address identified risks. Control 3: Assess and oversee the SaaS supplier Supplier assessment is particularly important because the customer may have limited direct access to the application's underlying infrastructure. Review the supplier's quality arrangements, change management, incident management, security practices, service continuity, documentation, and support model, as appropriate to the risks. Relevant evidence may include supplier assessments, audit reports, service agreements, security documentation, and information about development and release processes. Supplier certifications or independent reports may contribute to the assessment, but they do not automatically establish that the customer's configured application is fit for its regulated purpose. Document supplier responsibilities and customer responsibilities in a clear, maintained agreement or responsibility matrix. Control 4: Establish user requirements and configuration controls Document the functions and controls needed to support the intended process. Requirements may cover user permissions, approval workflows, electronic signatures where applicable, audit trails, report outputs, record retention, integrations, and exception handling. Assess the proposed configuration against these requirements. Distinguish supplier-standard functionality from customer-specific configuration and any custom interfaces or extensions. Maintain controlled records of configuration decisions and changes so that the validated state can be understood and reproduced where appropriate. Control 5: Build risk-based verification and testing Testing should demonstrate that the configured system performs its intended functions and provides adequate controls over critical processes and records. A suitable test strategy may include supplier evidence review, configuration verification, functional testing, negative testing, interface testing, access-control checks, and end-to-end business-process testing. For example, an electronic deviation workflow may need testing to demonstrate that required approvals cannot be bypassed, relevant records are retained, and access restrictions operate as intended. Use traceability to connect important requirements and risks to verification activities and documented results. Investigate discrepancies, record their impact, and approve their disposition according to the site's procedures. Testing should conclude with a documented assessment of whether the acceptance criteria have been met. Control 6: Protect data integrity and electronic records Data integrity controls should be designed around how regulated records are created, modified, reviewed, stored, retrieved, and retained. Depending on the intended use, relevant controls may include: Unique user accounts and role-based access. Appropriate audit trails and review procedures. Controlled electronic signatures, where applicable. Reliable record timestamps and secure authentication. Backup, restoration, and record-retrieval arrangements. Data retention and protection against unauthorized modification or deletion. For systems within its scope, FDA's guidance on 21 CFR Part 11: Electronic Records and Electronic Signatures provides important context for assessing applicable electronic-record and electronic-signature requirements. Part 11 should not be treated as a blanket label that automatically applies identically to every SaaS application. Applicability must be assessed in relation to the records, signatures, and underlying regulatory requirements. Control 7: Manage cloud updates, incidents, and disaster recovery Cloud applications may be updated frequently by their suppliers. A validation lifecycle should account for these releases rather than assuming the originally assessed configuration will remain unchanged. Define how the company receives release notifications, evaluates changes, assesses risks, performs additional verification, and documents approval where required. A change-impact assessment should consider whether an update affects critical functions, configured workflows, interfaces, audit trails, access controls, or validated requirements. Continuity planning should also address appropriate backup and recovery arrangements, service interruptions, incident escalation, and restoration of critical records and processes. Where relevant to the intended use, recovery tests should demonstrate that the organization's recovery arrangements function as expected. Control 8: Maintain lifecycle oversight and periodic review Cloud SaaS validation in pharma does not end when initial validation is approved. Establish ongoing oversight that may include supplier-performance review, recurring risk assessments, access reviews, incident trending, audit-trail review where applicable, change assessment, and verification of continued suitability. Periodic review frequency should be determined by system criticality, changes, incidents, supplier performance, and the organization's procedures. Retirement planning is also important. Define how records will be retained, exported, retrieved, and protected if the supplier relationship ends or the application is replaced. The goal is to maintain documented confidence in the system throughout its operational life. 4. A Practical Cloud SaaS Validation Lifecycle A structured lifecycle can help teams apply these controls efficiently. Phase 1 — Assessment: Define intended use, determine GxP relevance, establish the system boundary, and identify major risks. Phase 2 — Supplier evaluation: Assess available supplier documentation, responsibilities, quality practices, security controls, and service continuity. Phase 3 — Planning and configuration: Document requirements, select a proportionate validation approach, control configuration, and establish traceability. Phase 4 — Verification: Review relevant supplier evidence, execute risk-based tests, investigate discrepancies, and confirm acceptance criteria. Phase 5 — Release: Complete the required documentation and obtain appropriate quality and business approvals before regulated use. Phase 6 — Ongoing control: Monitor changes, supplier performance, incidents, access, data integrity, and continuing fitness for intended use. Phase 7 — Retirement: Plan controlled migration, retention, retrieval, and disposition of records. This is a practical lifecycle model, not a mandatory seven-phase regulatory sequence. Organizations should align it with their established quality system and applicable requirements. 5. Common Cloud SaaS Validation Mistakes to Avoid Assuming supplier validation is sufficient Supplier evidence can reduce duplication, but the customer must determine whether it adequately supports the intended use and configuration. Treating every function as equally critical A generic test checklist can consume resources without addressing the most significant risks. Prioritize requirements and tests according to documented risk. Ignoring ongoing releases A system can change after initial approval. Without effective change-impact assessment and oversight, the original validation evidence may no longer adequately reflect the live environment. Overlooking interfaces and data migration Data exchanged between systems can be altered, lost, duplicated, or mapped incorrectly. Verify relevant interfaces and migration activities according to their risk. Treating Part 11 as a product certificate A supplier's claim of compliance does not replace the customer's assessment of applicable requirements, system configuration, procedures, and intended use. 6. Frequently Asked Questions Does a SaaS application require validation in pharma? Where a cloud application supports regulated GxP activities, the organization should determine and document the appropriate assurance or validation activities based on intended use, risk, and applicable requirements. Not every application automatically falls within GxP validation scope. Can supplier documentation be used as validation evidence? Yes, relevant supplier documentation may be leveraged after an appropriate assessment. The organization remains responsible for establishing that the evidence, configuration, and verification activities support its intended use. What is the role of GAMP 5 in cloud validation? GAMP 5 provides a risk-based, lifecycle-oriented framework for assessing and controlling computerized systems. It supports proportionate verification and effective use of supplier knowledge. Does every SaaS application need 21 CFR Part 11 controls? No. Part 11 applicability depends on the relevant electronic records, electronic signatures, and underlying regulatory requirements. Organizations should assess scope rather than applying a uniform checklist without context. How often should a cloud SaaS system be reviewed? The appropriate frequency depends on system risk, supplier changes, incidents, performance, and internal procedures. Significant changes or incidents may require an assessment outside the routine review cycle. Conclusion Cloud SaaS validation in pharma requires a disciplined combination of risk assessment, supplier oversight, configuration control, verification, data-integrity safeguards, and ongoing lifecycle management. GAMP 5 helps pharmaceutical organizations develop a proportionate, evidence-based strategy while taking advantage of modern cloud technologies. The most effective approach is neither to duplicate every supplier activity nor to rely on supplier assurances without assessment. It is to establish which controls are needed, identify who is responsible for them, and maintain documented evidence that the system remains fit for its intended use. For further learning, explore Gaurav Dakshini's professional training and consulting resources and the related guide on CSV vs CSA in pharma.

Charolette Ervin

Biography

CONTACT US

QUICK LINKS

LEGAL PAGES

ABOUT

Learn on the go through our Skillup to Scaleup Movement!

© 2024 GAURAV DAKSHINI. All Rights Reserved. Managed by CONFIANCA TECHNOLOGIES LLP